Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Deoxyarbutin (CAS No.: 53936-56-4), a naturally derived tyrosinase inhibitor, has attracted widespread attention in recent years in the fields of skin whitening and anti-tumor treatment. Its unique bioactivity is not only reflected in its effective inhibition of melanin production, but also in its potential to promote apoptosis of melanoma cells and enhance the viability of mouse acinar cells. Research on deoxyarbutin not only enriches the pharmacological knowledge of tyrosinase inhibitors but also provides an important theoretical and practical basis for developing new safe and effective whitening and antitumor drugs.
This review aims to systematically summarize the chemical structure and physicochemical properties of deoxyarbutin, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and to explore its clinical application prospects and development trends, aiming to provide scientific reference and inspiration for researchers in related fields.
Deoxyarbutin is an phenolic glycoside with a chemical structure based on the deoxy derivative of arbutin, with a molecular formula of C10H14O4 and a molecular weight of 194.2300. Its structural features include the binding of a phenolic hydroxyl group to the glycoside part, which imparts excellent tyrosinase inhibitory activity. The LogP value of deoxyarbutin is 2.0482, indicating moderate lipid solubility that benefits its cell membrane permeability. The polar surface area (TPSA) is 38.6900, indicating that its molecules have certain polarity, which helps balance water solubility and bioavailability. Water solubility is 0.9622, indicating moderate solubility in aqueous phase, which facilitates formulation development.
Additionally, deoxyarbutin has a high blood-brain barrier penetration capacity, suggesting it may act in the central nervous system or carries potential central toxicity risks, but current research is insufficient. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames mutagenic test result was 0.0, indicating low genotoxicity risk and good safety.
Deoxyarbutin was originally derived from arbutin, which is widely found in plants such as bearberry leaves (Arctostaphylos uva-ursi) and bilberry (Vaccinium spp.). Deoxyarbutin is usually obtained through chemical synthesis or biotransformation methods, with few reports of direct extraction from natural plants.
Traditional extraction methods mainly target arbutin, using water extraction and alcohol extraction combined with column chromatography separation and purification techniques. The synthesis of deoxyarbutin is mostly done through the deoxy-reduction reaction, where reducing agents selectively remove hydroxyl groups from molecules to obtain deoxy derivatives. In recent years, the application of enzyme-catalyzed conversion technology has provided a gentler and more efficient approach for the preparation of deoxyarbutin.
Optimization of extraction and synthesis processes not only affects yield and purity but also relates to the stability of subsequent pharmacological activity and safety, making it an important direction for future research.
Deoxyarbutin, as an effective tyrosinase inhibitor, can significantly suppress key enzyme activities in melanin production. Tyrosinase (TYR) is the rate-limiting enzyme for melanin synthesis. Deoxyarbutin competitively inhibits its activity, reducing the conversion of tyrosine to dopaquinone, thereby decreasing melanin production. In vitro experiments have shown that deoxyarbutin exhibits significant tyrosinase inhibitory effects on both human melanocytes and melanoma cells.
Additionally, deoxyarbutin can regulate the expression of genes related to melanin production, including microenvironment transcription factors such as MITF (microcellular melanocyte transcription factor), MC1R (melanocyte-stimulating hormone receptor), DCT (dopaquinone transferase), and TYRP1 (tyrosinase-associated protein 1), further inhibiting melanin synthesis pathways and promoting skin whitening.
Recent studies have found that deoxyarbutin not only has skin whitening effects but also promotes apoptosis of melanoma cells. Its antitumor mechanism involves inducing cell cycle arrest, activating apoptotic signaling pathways, and inhibiting tumor cell proliferation. In vivo mouse model experiments show that deoxyarbutin can enhance acinar cell vitality and improve tissue function, suggesting its potential anti-tumor and tissue-protective effects.
Deoxyarbutin also exhibits antioxidant, anti-inflammatory, and other multiple biological activities, which can reduce skin damage caused by ultraviolet rays and protect skin cells from oxidative stress. It has a relatively high safety profile, with no obvious cytotoxicity or genotoxicity, providing favorable conditions for its development as a functional compound.
The main mechanism of action of deoxyarbutin focuses on the regulation of tyrosinase and its related signaling pathways. By binding to the active site of tyrosinase, deoxyarbutin blocks the conversion of tyrosine to dopa, inhibiting the key step of melanin production. Additionally, deoxyarbutin affects the signal transduction network within melanocytes, regulating MITF expression and activity. As the main regulator of melanin production, MITF has downstream target genes including TYR, TYRP1, and DCT, all regulated.
MC1R acts as a receptor for melanocytes, mediating α-MSH signaling and promoting melanin synthesis. Deoxyarbutin indirectly affects melanin production by regulating MC1R expression or activity. ASIP (Melanin-stimulating hormone antagonist protein), as an antagonist of MC1R, also participates in the regulatory network of deoxyarbutin.
In terms of antitumor effects, deoxyarbutin-induced apoptosis in melanoma cells may involve the regulation of mitochondrial pathways and cell cycle regulatory proteins, with specific molecular mechanisms requiring further research.
The molecular weight of deoxyarbutin is 194.23, conforming to the Lipinski rule. The LogP value of 2.0482 indicates good lipid solubility, which facilitates cell membrane penetration and oral absorption. TPSA was 38.69, indicating moderate polarity and favorable for distribution in vivo. Moderate water solubility (0.9622), facilitating formulation development and improved bioavailability.
In terms of safety, deoxyarbutin did not show hERG channel inhibitory activity, reducing the risk of cardiotoxicity. Ames test was negative, with low genotoxicity risk and meeting drug safety requirements. Its relatively high blood-brain barrier penetration capacity suggests possible central nervous system activity, but potential central side effects should also be considered.
Pharmacokinetic studies show that deoxyarquatin has good bioavailability after oral administration, is widely distributed in the body, and its metabolic pathway mainly involves hepatic enzyme systems, with excretion primarily via the kidneys. The effects of its metabolites on safety and activity still require further clarification.
Deoxyarbutin, as a new type of natural tyrosinase inhibitor, has remarkable skin whitening effects and good safety, making it a research hotspot in the cosmetics and pharmaceutical fields. Its oral effectiveness offers new ideas for the development of skin whitening products, breaking through the limitations of traditional topical whitening agents.
In the field of anti-tumor therapy, the role of deoxyarbutin in promoting apoptosis in melanoma cells offers potential for its development as an adjunct anticancer drug. More preclinical and clinical studies are needed in the future to verify efficacy and safety, clarify dosage ranges, and administration regimens.
In addition, the antioxidant and anti-inflammatory multiple biological activities of deoxyarbutin give it broad application prospects in skin protection and anti-aging fields. By integrating modern pharmaceutical technologies, such as nanocarriers and sustained-release formulations, it is expected to improve bioavailability and targeting, expanding its clinical application range.
Future research should focus on in-depth elucidation of the mechanism of deoxyarbutin, optimization of pharmacokinetics, clinical safety evaluation, and multi-target synergy, to promote its translation from laboratory research to clinical practice.
Deoxyarbutin, as a natural product derivative with a unique structure and multiple bioactive properties, demonstrates remarkable potential for skin whitening and anti-tumor effects. Its excellent druggability parameters and safety provide a solid foundation for its development. Although research on its mechanism of action and clinical applications is still in its early stages, with continuous advances in related technologies and research, deoxyarbutin is expected to become an important candidate molecule for future natural product drug development.
Systematic and in-depth pharmacological research, reasonable dosage formulation design, and scientific clinical validation will be key to advancing the clinical application of deoxyarbutin. We look forward to more high-quality research achievements in the future to help deoxyarbutin play a greater role in skin whitening and anti-tumor fields, benefiting human health.
